The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.

Trial Profile

The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms RAI-skip
  • Most Recent Events

    • 27 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 08 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top